MSME (Udyam registered) Ministry of MSME
- Category
- Micro (2022-23)
- Udyam number
- UDYAM-TS-02-0001806
Spanus Pharmaceuticals Private Limited
Spanus Pharmaceuticals Private Limited - chemicals and materials in Hyderabad, Telangana, India. FY 2026 financials & compliance.
Revenue · FY 2022
₹2.83 Cr
▼ 19% YoY
Net loss · FY 2022
₹56.71 Lakh
Net margin -20%
EBITDA · FY 2022
-₹62.09 Lakh
EBITDA margin -21.9%
Authorised capital
₹10 Lakh
Registered with MCA
Paid-up capital
₹1 Lakh
Issued & subscribed
Company age
7 yrs
Est. 2019
Employees · EPFO
6
Provident fund records
Directors on board
3
As per MCA filings
About Spanus Pharmaceuticals Private Limited
Data last updated:
Spanus Pharmaceuticals Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the organic chemicals and compounds segment of the chemicals and materials sector. It was incorporated on 25 January 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24239TG2019PTC130023. The company has 1 GST registration on record, which is no longer active.
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors including Udaya Kiran Perla (Managing Director) and Sri Chandana Modukuri.
Its last annual general meeting (AGM) was held on 30 September 2022, and its latest financial statements are for the year ended 31 March 2022. The registered office is at Flat No. 201 2nd Floor Plot No. 239 Sri Rama Nilayam Kamalapuri Colony, Hyderabad, Telangana, India – 500073.
As per the financials filed for FY 2022, the company reported a revenue of ₹2.83 Cr, a decline of 19% compared to the previous year. For the same year it recorded a net loss of ₹56.71 Lakh (net margin -20%) and EBITDA of -₹62.09 Lakh (EBITDA margin -21.9%).
The company has about 6 employees on its provident fund (EPFO) records.
Spanus Pharmaceuticals Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-02-0001806). The current compliance status is marked as compliant by the Registrar of Companies.
Company details
CIN U24239TG2019PTC130023
Registration Number 130023
Incorporation Date 25 January 2019
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2022
Date of Balance Sheet 31 March 2022
Compliance Status Active Compliant
MSME Classification Micro
Udyam Registration UDYAM-TS-02-0001806
Key People
Udaya Kiran Perla Managing Director Sri Chandana Modukuri Director Rama Subrahmanyam Sana Director Recognitions & Rankings of Spanus Pharmaceuticals
Contact details
Spanus Pharmaceuticals Private Limited's registered office is in Hyderabad, Telangana. Its e-mail address is in the company report.
- Email
- Registered AddressFlat No. 201 2nd Floor Plot No. 239 Sri Rama Nilayam Kamalapuri Colony, Hyderabad, Telangana, India – 500073
- IndustryChemicals and Materials, Organic Chemicals & Compounds
To see the full contact details of Spanus Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Spanus Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Spanus Pharmaceuticals is trade. In detail, this covers retail trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G2 | Retail Trading |
To see the full business activity and turnover split of Spanus Pharmaceuticals Private Limited, buy the company report.
Financials of Spanus Pharmaceuticals Private Limited
FY 2022 filings availableSpanus Pharmaceuticals Private Limited reported revenue of ₹2.83 Cr (down 19% YoY) for FY 2022.
Revenue · FY 2022
₹2.83 Cr ▼ 19%
Net loss · FY 2022
₹56.71 Lakh margin -20%
EBITDA · FY 2022
-₹62.09 Lakh margin -21.9%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 19%
EBITDA CAGR growth
1 year
▲ 45%
Revenue fell 19% in the latest year. EBITDA rose 45% in the latest year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | ₹2.83 Cr | |||
| Other Income | ||||
| Total Revenue | ||||
| Cost of Materials Consumed | ||||
| Employee Benefit Expense | ||||
| Finance Costs | ||||
| Depreciation and Amortisation | ||||
| Other Expenses | ||||
| Total Expenses | ||||
| EBITDA | -₹62.09 Lakh | |||
| Profit Before Tax | ||||
| Tax Expense | ||||
| Net Profit (PAT) | -₹56.71 Lakh | |||
| Balance Sheet | ||||
| Share Capital | ||||
| Reserves and Surplus | ||||
| Net Worth (Total Equity) | ||||
| Long-term Borrowings | ||||
| Short-term Borrowings | ||||
| Trade Payables | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | -21.9% | |||
| Net Profit Margin | -20% | |||
| Return on Equity (ROE) | ||||
| Return on Capital Employed (ROCE) | ||||
| Return on Assets (ROA) | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Quick Ratio | ||||
| Debt-to-Equity Ratio | ||||
| Interest Coverage Ratio | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Payable Days | ||||
| Inventory Days | ||||
| Revenue Growth | ||||
| Net Profit Growth | ||||
To see the full financial statements and ratios of Spanus Pharmaceuticals Private Limited, buy the company report.
Board of directors of Spanus Pharmaceuticals Private Limited
Spanus Pharmaceuticals has 3 directors on record. No former directors are listed.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Udaya Kiran Perla Also directs: Unistar Pharma Private Limited, Unicon Pharma Private Limited, Layerly Pharmaceuticals Private Limited and 3 more | Managing Director | 25 Jan 2019 | 7 Years 8 Months | Current |
| Sri Chandana Modukuri | Director | 25 Jan 2019 | 7 Years 8 Months | Current |
| Rama Subrahmanyam Sana Also directs: Layspan Pharmaceuticals Private Limited | Director | 25 Jan 2019 | 7 Years 8 Months | Current |
Legal cases
No court or tribunal cases involving Spanus Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Spanus Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Spanus Pharmaceuticals Private Limited has a workforce of 6 employees on its EPFO records as of Apr 08, 2024, across 1 active EPFO establishment.
Employee count
6
Active EPFO establishments
1
Employee growth
-87.5%
GST
Spanus Pharmaceuticals has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.
Total GSTINs
1
Cancelled / inactive
1
To see the full GST registrations and return filing status of Spanus Pharmaceuticals Private Limited, buy the company report.
Recent activity
Spanus Pharmaceuticals Private Limited has 3 board changes on record since 2019: 3 appointments. The latest: Rama Subrahmanyam Sana was appointed as Director on 25 Jan 2019.
AGM
Spanus Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2022 as per latest MCA records.
Filing
Spanus Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2022 with Roc Hyderabad.
Appointed
Rama Subrahmanyam Sana was appointed as Director.
Appointed
Sri Chandana Modukuri was appointed as Director.
Appointed
Udaya Kiran Perla was appointed as Managing Director.
Incorporation
25 Jan 2019
Spanus Pharmaceuticals Private Limited was registered on 25 Jan 2019 with Roc Hyderabad & aged 7 years 8 months as per MCA records.
Frequently asked questions
Spanus Pharmaceuticals is an active private limited company based in Hyderabad, Telangana, India. The company works in organic chemicals and compounds, within the chemicals and materials industry. It was incorporated on 25 January 2019 (7+ years old) and is registered under CIN U24239TG2019PTC130023.
Spanus Pharmaceuticals has 3 current directors:
- Udaya Kiran Perla - Managing Director
- Sri Chandana Modukuri - Director
- Rama Subrahmanyam Sana - Director
The latest financial statements of Spanus Pharmaceuticals on record with the MCA are for the year ended 31 March 2022. Its last annual general meeting was held on 30 September 2022. Year-wise statements from FY 2019 are in the company report.
No. Spanus Pharmaceuticals has 1 GST registration on record and it is cancelled or inactive.
The CIN (Corporate Identification Number) of Spanus Pharmaceuticals is U24239TG2019PTC130023. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Spanus Pharmaceuticals was incorporated on 25 January 2019, making it 7+ years old. It is registered with the Registrar of Companies, Hyderabad.
Rama Subrahmanyam Sana was appointed as Director on 25 Jan 2019. Sri Chandana Modukuri was appointed as Director on 25 Jan 2019. Udaya Kiran Perla was appointed as Managing Director on 25 Jan 2019.
Yes, Spanus Pharmaceuticals is registered as a micro enterprise under Udyam registration (number: UDYAM-TS-02-0001806).
The registered office of Spanus Pharmaceuticals is at Flat No. 201 2nd Floor Plot No. 239 Sri Rama Nilayam Kamalapuri Colony, Hyderabad, Telangana, India – 500073.
Spanus Pharmaceuticals operates in the chemicals and materials industry, in the organic chemicals and compounds segment.